Genmab A/S announced its intention to submit in the first half of 2025 a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for subcutaneous epcoritamab, a bispecific antibody being investigated in combination with rituximab and Lenalidomide (R2) for the treatment of adult patients with relapsed or refractory (R R) follicular lymphoma (FL), following at least one prior systemic therapy. Epcoritamab is currently approved by the FDA under Accelerated Approval as a monotherapy for the treatment of adults with R R FL after two or more lines of systemic therapy. EpcoritAMab to Submit Supplemental Biologics License Application (SBLA) to U.S. Food and drug Administration for Epcoritamab Plus Rituximab and Lenalomide (R2) in Patients with Relapsed Refractory Follicular Lymphoma (FL) manufacturing, the lack of market acceptance of products, inability to manage growth, the competitive environment in relation to business area and markets, inability to attract and retainably qualified personnel, the unenforceability or lack of protection of patents and proprietary rights.